Henry Schein (HSIC) Stock Price, News & Analysis

Company Overview

Henry Schein, Inc. is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes. This includes practice management software, e-commerce platforms, digital imaging systems, and advanced sterilization and infection control solutions. The company also offers financial services, consulting, and supply chain management programs designed to help healthcare practices optimize inventory, reduce operating costs and comply with regulatory requirements.

Founded in 1932 by Henry Schein in Queens, New York, the company has grown from a small health products supplier into a Fortune 500 organization headquartered in Melville, New York. Over the decades, Henry Schein has expanded through strategic acquisitions and organic growth, establishing a presence in more than 30 countries and serving over one million customers worldwide. Its global logistics network and local market expertise enable rapid delivery of products and responsive support for healthcare professionals across North America, Europe, Asia Pacific, Latin America and Africa.

Under the leadership of Chairman and Chief Executive Officer Stanley M. Bergman, who joined the company in the late 1980s, Henry Schein has pursued a strategy centered on customer service excellence, innovation and partnerships. The company collaborates with manufacturers, technology developers and professional associations to introduce new solutions and best practices to the marketplace. With a commitment to sustainability and community engagement, Henry Schein continues to invest in research, education and outreach programs that support the health and well-being of practitioners and patients around the world.

Key Stats

• Today's Range: $87.57 to $88.83
• 50-Day Range: $75.74 to $89.59
• 52-Week Range: $61.94 to $92.18
• Volume: 649,693 shs
• Average Volume: 1.46 million shs
• Market Capitalization: $9.82 billion
• P/E Ratio: 25.69
• Dividend Yield: N/A
• Price Target: $92.27
• Consensus Rating: Hold

Henry Schein Stock Analysis - MarketRank™

Henry Schein scored higher than 74% of companies evaluated by MarketBeat, and ranked 235th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

Henry Schein has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on no strong buy ratings, 8 buy ratings, 6 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Henry Schein is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Henry Schein has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.84%

Earnings Growth

Earnings for Henry Schein are expected to grow by 10.84% in the coming year, from $5.35 to $5.93 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Henry Schein is 25.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.59.

Price to Earnings Ratio vs. Sector

The P/E ratio of Henry Schein is 25.69, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.55.

Price to Earnings Growth Ratio

Henry Schein has a PEG Ratio of 1.68. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Henry Schein has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.79% of the float of Henry Schein has been sold short.

Short Interest Ratio / Days to Cover

Henry Schein has a short interest ratio ("days to cover") of 5.01.

Change versus previous month

Short interest in Henry Schein has recently decreased by 8.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Henry Schein does not currently pay a dividend.

Dividend Growth

Henry Schein does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.65

News Sentiment

Henry Schein has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Henry Schein this week, compared to 8 articles on an average week.

Search Interest

Only 1 people have searched for HSIC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $691,900.00 in company stock, which represents 0.0070% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Henry Schein insiders have bought more of their company's stock than they have sold. Specifically, they have bought $691,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.89% of the stock of Henry Schein is held by insiders.

Percentage Held by Institutions

96.62% of the stock of Henry Schein is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 8/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Distributors
• Current Symbol: NASDAQ:HSIC
• CIK: 1000228
• Web: www.henryschein.com
• Phone: (631) 843-5500
• Fax: 631-843-5541
• Employees: 25,000
• Year Founded: 1932

Price Target and Rating

• Average Price Target for Henry Schein: $92.27
• High Price Target: $112.00
• Low Price Target: $64.00
• Potential Upside/Downside: +4.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.47
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.43
• Trailing P/E Ratio: 25.69
• Forward P/E Ratio: 16.47
• P/E Growth: 1.68
• Net Income: $398 million
• Net Margins: 2.96%
• Pretax Margin: 4.07%
• Return on Equity: 15.97%
• Return on Assets: 5.56%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 1.32
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: $13.60 billion
• Price / Sales: 0.72
• Cash Flow: $7.77 per share
• Price / Cash Flow: 11.34
• Book Value: $34.25 per share
• Price / Book: 2.57

Miscellaneous

• Outstanding Shares: 111,447,000
• Free Float: 110,455,000
• Market Cap: $9.82 billion
• Optionable: Optionable
• Beta: 0.80